Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.54 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.54 |
| ▸ | AXL | P30530 | 1/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | FADS1 | O60427 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22593285 | 0.81 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL2878014 | 0.81 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL27409928 | 0.80 | PDE4B (0.51) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL21567313 | 0.80 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| Hydrochloric Acid SCHEMBL5642444 | 0.79 | PDE4A (0.54) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL13653497 | 0.78 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL5455935 | 0.76 | EGFR (0.62) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL5369046 | 0.75 | EGFR (0.60) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL5368863 | 0.74 | S1PR2 (0.56) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL24466943 | 0.74 | PIP4K2C (0.62) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3151669-B1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-20200283398-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2020-09-10 | — | — | US | disclosed |
| EP-2074115-B1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20170144980-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2017-05-25 | — | — | US | disclosed |
| US-20170144980-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283398-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | CYP51A1, DPM1, NOX1 | PDE4A 2699/4885PDE4B 2017/4885PDE4C 3198/4885 |
| US-20170144980-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | CYP51A1, DPM1, NOX1 | PDE4A 2699/4885PDE4B 2017/4885PDE4C 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.